Zacks Investment Research on MSN
Lilly bets on next-generation obesity drugs to stay ahead
Eli Lilly and Company LLY is a leader in the fast-growing diabetes and obesity market, driven by its blockbuster ...
People taking Eli Lilly’s next-generation GLP-1 obesity drug retatrutide shed more pounds than any other weight-loss drug during a late-stage trial, the company said Thursday. Patients using the ...
Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have made headlines over the past few years for selling one of the world's most in-demand products: weight loss drugs. Lilly is the maker of ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s obesity pill ...
April 1 (Reuters) - The U.S. FDA on Wednesday approved Eli Lilly's weight-loss pill, setting up its next battle with rival Novo Nordisk for the millions of Americans seeking highly effective GLP-1 ...
Foundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill. Retatrutide, a subcutaneous triple hormone receptor agonist in phase 3 trials, could be a game changer. If both drugs ...
Eli Lilly paused its obesity awareness campaign in India after the nation's drugs regulator warned the company it could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results